Top Health Care Stocks
Health care stocks were edging higher, including a less than 0.1% gain for the NYSE Health Care Index in recent trade. Shares of health care companies in the S&P 500 also were up just under 0.1% as a group while the Nasdaq Biotechnology index was climbing slightly more than 0.1%.
Among health care stocks moving on news:
(-) Abiomed ( ABMD ) fell nearly 6% on Thursday after the cardiac medical device company reported Q4 revenue lagging analyst projections, rising to $207.1 million during the three months ended March 31 from $174.4 million during the same quarter last year but missing the Capital IQ consensus by $11.8 million. It also sees its FY20 revenue increasing 17% to 23% over the prior-year period, projecting between $900 million to $945 million in revenue for the 12 months ending next March. Analysts, on average, are looking for $988.4 million in annual sales.
In other sector news:
(+) ACADIA Pharmaceuticals ( ACAD ) climbed 6% on Thursday after the specialty drugmaker saw its revenue rise 28.8% over year-ago levels to $62.96 million, topping the $60.93 million analyst mean. The company also raised the bottom end of its expected sales range for its Nuplazid medication by $5 million, now looking for between $280 million and $300 million in sales for the Parkinson's treatment.
(+) AmerisourceBergen ( ABC ) rose almost 6% after the pharmaceuticals distributor reported non-GAAP net income of $2.11 per share during its fiscal Q2 ended March 31, up from $1.94 per share during the same quarter last year and beating the Capital IQ by $0.15 per share. It also raised its FY19 earnings outlook by $0.05 on both sides of its prior forecast range, now expecting between $6.70 to $6.90 per share. The Street is at $6.77 per share.
(-) Canopy Growth Corp ( CGC ) fell 5% on Thursday after the Canadian medical marijuana company said it acquired C3 Cannabinoid Compound Co, paying CAD342.9 million in cash for the German prescription medicines company.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of NASDAQ, Inc.